Hematopoietic AC133+ stem cell therapy for patients with severe peripheral vascular disease

L. Statkute, Y. Oyama, W. Pearce, K. Yaung, M. Villa, T. Shook, R. Clifton, L. Verda, N. Krosnjar, R.K. Burt
2006 Biology of Blood and Marrow Transplantation  
followed by successful engraftment. Grade 2 nausea and grade 1 emesis were seen briefly on day 2 of TMI. Skin erythema, oral mucositis, esophagitis, and enteritis were not observed. Conclusions: This report demonstrates the feasibility to selectively deliver myeloablative doses of radiation to bone and marrow using Tomotherapy. Organ doses were substantially lower than those associated with standard TBI and predict for the potential to significantly reduce associated toxicities, allowing for
more » ... e escalation. Ongoing trials will define the maximum TMI/TMLI doses achievable and define the potential advantages and limitations of this new approach for patients undergoing HSCT (Table1). Median Organ Doses (Gy) for TMI 12 and 20 Gy vs Standard TBI 12 Gy in a 20 Year Old Patient with AML
doi:10.1016/j.bbmt.2005.11.284 fatcat:5u7as57cxrbwti2zjzrmx7eiw4